- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05232110
Compassionate Use of Pozelimab
October 18, 2023 updated by: Regeneron Pharmaceuticals
Provide compassionate use of pozelimab
Study Overview
Status
Available
Conditions
Intervention / Treatment
Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Requests for compassionate use must be initiated by a treating physician. Physicians should contact
- Phone Number: 844-734-6643
- Email: CompassionateUse_Requests@regeneron.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
January 28, 2022
First Submitted That Met QC Criteria
January 28, 2022
First Posted (Actual)
February 9, 2022
Study Record Updates
Last Update Posted (Actual)
October 23, 2023
Last Update Submitted That Met QC Criteria
October 18, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Urologic Diseases
- Urological Manifestations
- Bone Marrow Diseases
- Hematologic Diseases
- Gastrointestinal Diseases
- Urination Disorders
- Intestinal Diseases
- Anemia
- Proteinuria
- Anemia, Hemolytic
- Myelodysplastic Syndromes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Hemoglobinuria
- Hemoglobinuria, Paroxysmal
- Protein-Losing Enteropathies
Other Study ID Numbers
- R3918-Pozelimab
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
Apellis Pharmaceuticals, Inc.RecruitingParoxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal HemoglobinuriaMalaysia, United States, Czechia, France, Netherlands, Serbia, Spain, Thailand, United Kingdom
-
Novartis PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria PNHLithuania, Japan, Czechia
-
Ra PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United States
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, New Zealand, Korea, Republic of, Italy
-
AKARI TherapeuticsCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)Kazakhstan, Lithuania, Sri Lanka
-
Alexion PharmaceuticalsTerminatedParoxysmal Nocturnal Hemoglobinuria (PNH)United States, Czech Republic, Italy, Poland, United Kingdom
-
AlexionActive, not recruitingParoxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
-
AlexionCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)Belgium, France, Italy, Japan, Spain, Taiwan, United Kingdom, United States, Canada, Czechia, Germany, Sweden, Singapore, Korea, Republic of, Russian Federation, Austria, Poland, Argentina, Australia, Brazil, Estonia, Malaysia, Mexico, Thaila... and more
-
Apellis Pharmaceuticals, Inc.CompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United States
-
AlexionCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
Clinical Trials on Pozelimab
-
Regeneron PharmaceuticalsRecruitingGeneralized Myasthenia GravisKorea, Republic of, Japan, Spain, United States, Germany, Italy, Canada, Georgia, India, Belgium, Poland, Taiwan, Australia, Denmark, France, Turkey, Serbia, United Kingdom, Czechia
-
Regeneron PharmaceuticalsCompleted
-
Regeneron PharmaceuticalsAvailableCD55-Deficient Protein-Losing Enteropathy
-
Regeneron PharmaceuticalsTerminatedParoxysmal Nocturnal HemoglobinuriaHong Kong, Korea, Republic of, Malaysia, Hungary, Taiwan, United Kingdom
-
Regeneron PharmaceuticalsActive, not recruitingCD55-deficient Protein-losing Enteropathy | CHAPLEUnited States, Thailand, Turkey
-
Regeneron PharmaceuticalsCompletedParoxysmal Nocturnal HemoglobinuriaKorea, Republic of, Taiwan, Malaysia, Hong Kong, Hungary, United Kingdom
-
Regeneron PharmaceuticalsAvailableParoxysmal Nocturnal Hemoglobinuria
-
Regeneron PharmaceuticalsCompleted
-
Regeneron PharmaceuticalsCompletedParoxysmal Nocturnal HemoglobinuriaUnited Kingdom
-
Regeneron PharmaceuticalsRecruitingParoxysmal Nocturnal HemoglobinuriaTaiwan, Korea, Republic of, Turkey, Spain, Thailand, Singapore, Japan, Canada, Malaysia, Poland, Italy